NL300411I1 - Werkwijze voor het met gebruikmaking van nieuwe cyanilerende reagentia - Google Patents

Werkwijze voor het met gebruikmaking van nieuwe cyanilerende reagentia

Info

Publication number
NL300411I1
NL300411I1 NL300411C NL300411C NL300411I1 NL 300411 I1 NL300411 I1 NL 300411I1 NL 300411 C NL300411 C NL 300411C NL 300411 C NL300411 C NL 300411C NL 300411 I1 NL300411 I1 NL 300411I1
Authority
NL
Netherlands
Prior art keywords
moiety
cyanilizing
reagents
new
immunogenic
Prior art date
Application number
NL300411C
Other languages
English (en)
Original Assignee
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson H M Found Military Med filed Critical Jackson H M Found Military Med
Publication of NL300411I1 publication Critical patent/NL300411I1/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NL300411C 1993-09-22 2009-09-24 Werkwijze voor het met gebruikmaking van nieuwe cyanilerende reagentia NL300411I1 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12449193A 1993-09-22 1993-09-22
PCT/US1994/010658 WO1995008348A1 (en) 1993-09-22 1994-09-21 Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs

Publications (1)

Publication Number Publication Date
NL300411I1 true NL300411I1 (nl) 2009-12-01

Family

ID=22415196

Family Applications (2)

Application Number Title Priority Date Filing Date
NL300412C NL300412I1 (nl) 1993-09-22 2009-09-24 Werkwijze voor het met gebruikmaking van nieuwe cyanilerende reagentia
NL300411C NL300411I1 (nl) 1993-09-22 2009-09-24 Werkwijze voor het met gebruikmaking van nieuwe cyanilerende reagentia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL300412C NL300412I1 (nl) 1993-09-22 2009-09-24 Werkwijze voor het met gebruikmaking van nieuwe cyanilerende reagentia

Country Status (13)

Country Link
US (2) US5651971A (nl)
EP (1) EP0720485B1 (nl)
JP (1) JP3828145B2 (nl)
KR (1) KR100376361B1 (nl)
AT (1) ATE254475T1 (nl)
AU (1) AU678613B2 (nl)
CA (1) CA2171942C (nl)
DE (2) DE122009000058I1 (nl)
ES (1) ES2210262T3 (nl)
FR (1) FR12C0059I2 (nl)
NL (2) NL300412I1 (nl)
NZ (1) NZ274376A (nl)
WO (1) WO1995008348A1 (nl)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
NZ274376A (en) * 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
AU712981B2 (en) * 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
NZ306316A (en) * 1995-04-17 2001-06-29 Smithkline Beecham Biolog S use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
AU2429397A (en) * 1996-03-29 1997-10-22 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
DK0912195T3 (da) 1996-06-25 2009-05-18 Pepscan Systems Bv Vaccine indeholdende antigener bundet til bærestoffer gennem labile bindinger
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
DE69826851T2 (de) * 1997-04-24 2005-02-10 Henry M. Jackson Foundation For The Advancement Of Military Medicine Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US6284250B1 (en) * 1998-02-05 2001-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
AU3005499A (en) * 1998-03-16 1999-10-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties
EP1069909B1 (en) * 1998-04-10 2007-06-13 Andrew Lees Conjugate vaccines for the prevention of dental caries
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO1999064603A2 (en) * 1998-06-12 1999-12-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220
CA2338093C (en) * 1998-07-20 2010-11-30 Shousun C. Szu Vaccines against escherichia coli o157 infection
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
DE60038166T2 (de) 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PE20020126A1 (es) 2000-06-29 2002-04-27 Smithkline Beecham Biolog Composicion de vacuna
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
CN1787839B (zh) * 2003-03-07 2011-09-28 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
CA2540896C (en) 2003-10-02 2015-06-02 Chiron Srl Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
AU2005209303A1 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
DK1740217T3 (da) 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7456000B2 (en) * 2004-08-26 2008-11-25 Siemens Healthcare Diagnostics Inc. Deactivation of linking moieties in antibody-enzyme conjugates
BRPI0515520A (pt) 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
SI1868645T1 (sl) 2005-04-08 2012-04-30 Wyeth Llc Večvalentni pnevmokokni sestavek konjugata polisaharid-protein
CA2611960C (en) 2005-06-27 2015-05-05 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising n.meningitidis capsular saccharide conjugates
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1993604B1 (en) 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
AU2007229449A1 (en) 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
EA015833B1 (ru) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
PE20090212A1 (es) 2007-05-02 2009-03-30 Glaxosmithkline Biolog Sa Kit de vacuna para la inmunizacion primaria
JP2010531330A (ja) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
AU2009302582A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Preparations and method for Protein A (SPA) variants
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
US9125951B2 (en) 2009-06-22 2015-09-08 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
PT2445522T (pt) 2009-06-22 2017-10-04 Wyeth Llc Composições imunogénicas de antigénios de staphylococcus aureus
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
WO2011036560A2 (en) 2009-09-23 2011-03-31 Novartis Ag Glycoconjugate compositions and methods for treatment of hiv
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP5960055B2 (ja) 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌fHBPポリペプチド
WO2011084705A2 (en) 2009-12-17 2011-07-14 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago PROTEIN A (SPA) ANTIBODY COMPOSITIONS AND METHODS AS AN IMMUNE RESPONSE AMPLIFIER
US8383783B2 (en) 2010-04-23 2013-02-26 Serum Institute Of India, Ltd. Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago プロテインA(SpA)変種に関連する組成物および方法
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 感染防御ブドウ球菌抗原が関与する方法および組成物
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013252883B2 (en) 2012-04-26 2018-05-17 University Of Chicago Staphylococcal coagulase antigens and methods of their use
US20150273036A1 (en) 2012-10-12 2015-10-01 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
JP2016501550A (ja) 2012-12-27 2016-01-21 グリコヴァキシン アーゲー Crm197に関する方法及び組成物
US8916173B2 (en) 2013-03-08 2014-12-23 Crucell Holland B.V. Acellular pertussis vaccine
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
MY194920A (en) * 2013-10-11 2022-12-23 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP4286000A3 (en) 2014-01-21 2024-02-14 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3206112A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DK3099800T3 (da) 2014-01-31 2021-01-11 Fina Biosolutions Llc Ekspression og oprensning af crm197 og beslægtede proteiner
US10392424B2 (en) 2014-02-28 2019-08-27 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3229833A1 (en) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Method of treatment
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
EP3270897A4 (en) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
MX368897B (es) 2015-05-04 2019-10-21 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
PL3313436T3 (pl) 2015-06-23 2021-06-14 Biological E Limited Wielowartościowa skoniugowana szczepionka przeciw pneumokokom
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
EP3269385A1 (en) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3493837B1 (en) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017321039B2 (en) 2016-09-02 2021-03-18 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
BR112019004303A2 (pt) * 2016-09-06 2019-05-28 Lg Chemical Ltd composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
CN109789198A (zh) 2016-09-30 2019-05-21 生物E有限公司 包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
MX2019008564A (es) 2017-01-20 2019-09-19 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas.
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
BR112019014397A2 (pt) 2017-01-31 2020-02-11 Pfizer Inc. Composições de neisseria meningitidis e métodos das mesmas
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
BR112020004509A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
BR122021023687A8 (pt) 2017-12-06 2023-02-07 Merck Sharp & Dohme Usos de composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN112673054A (zh) 2018-07-19 2021-04-16 葛兰素史密丝克莱恩生物有限公司 用于制备干燥多糖的方法
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220296695A1 (en) 2018-12-19 2022-09-22 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX2021013736A (es) 2019-05-10 2021-12-10 Glaxosmithkline Biologicals Sa Produccion de conjugados.
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
KR20220069992A (ko) 2019-09-27 2022-05-27 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CN114728051A (zh) 2019-11-22 2022-07-08 葛兰素史克生物有限公司 细菌糖糖缀合物疫苗的剂量和施用
IL295713A (en) 2020-02-21 2022-10-01 Pfizer Isolation of saccharides
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
JP2023529925A (ja) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナノ粒子ワクチンを使用する細菌免疫化
WO2021259742A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
WO2022043855A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US20220088165A1 (en) 2020-09-17 2022-03-24 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
US20230405104A1 (en) 2020-10-20 2023-12-21 Shanghai Reinovax Biologics Co., Ltd Proteoglycan conjugate and application thereof
US20230383324A1 (en) 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
CN114965784B (zh) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 多糖活化度的测定方法
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE343210B (nl) * 1967-12-20 1972-03-06 Pharmacia Ab
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
DE3540076A1 (de) * 1985-11-12 1987-05-14 Boehringer Mannheim Gmbh Verfahren zur stabilisierung von creatinkinase
DE3541186A1 (de) * 1985-11-21 1987-05-27 Boehringer Mannheim Gmbh Wasserloesliche, stabilisierte peroxidasederivate, verfahren zu ihrer herstellung und verwendung zur bestimmung von wasserstoffperoxid
US5177059A (en) * 1989-11-15 1993-01-05 Sandoz Ltd. Polymyxin B conjugates
ATE111746T1 (de) * 1989-11-15 1994-10-15 Sandoz Ag Polymyxinkonjugate.
EP0911036A3 (en) * 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
NZ274376A (en) * 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs

Also Published As

Publication number Publication date
DE122009000058I1 (de) 2009-12-31
US5651971A (en) 1997-07-29
FR12C0059I2 (fr) 2016-10-21
AU678613B2 (en) 1997-06-05
DE69433341D1 (de) 2003-12-24
EP0720485B1 (en) 2003-11-19
ATE254475T1 (de) 2003-12-15
AU7839194A (en) 1995-04-10
NZ274376A (en) 1997-11-24
WO1995008348A1 (en) 1995-03-30
CA2171942C (en) 2010-12-14
CA2171942A1 (en) 1995-03-30
JP3828145B2 (ja) 2006-10-04
EP0720485A1 (en) 1996-07-10
KR100376361B1 (ko) 2003-07-18
US5693326A (en) 1997-12-02
ES2210262T3 (es) 2004-07-01
FR12C0059I1 (nl) 2012-12-14
DE69433341T2 (de) 2004-04-15
NL300412I1 (nl) 2009-12-01
JPH09502978A (ja) 1997-03-25
KR960704572A (ko) 1996-10-09

Similar Documents

Publication Publication Date Title
NL300412I1 (nl) Werkwijze voor het met gebruikmaking van nieuwe cyanilerende reagentia
NZ304715A (en) Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
WO1995008348B1 (en) Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
ATE354644T1 (de) Katalytischer antikörper gegen aldolase
DE69632546D1 (de) Ob proteinderivate mit verlängerter halbwertzeit
EP1097992A3 (en) Modified bioluminescent proteins and their use
WO2005014655A3 (en) Conjugates of hydroxyalkyl starch and a protein
DE69325096T2 (de) Morphinderivate sowie deren konjugate und labels mit proteinen und polypeptiden
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
SE9301270D0 (sv) Biosensor
IL132380A0 (en) Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
BR9509001A (pt) Proteína que objetiva virions de HIV com base em moléculas de fusão HIV-1 VPR
AU3076601A (en) Chemically-programmable immunity
TR199800505T1 (xx) Difluorometan �retimi i�in proses.
CA2173822A1 (en) Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in e. coli
AU2002215904A1 (en) Compounds with a branched linker
AU1125192A (en) Fusion proteins for prodrug activation, the preparation and use thereof
ATE285474T1 (de) Haemophilus adhäsionsproteinen
ATE193534T1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
GB2317387A (en) Chemical compounds
AU5045493A (en) Process for preparing conjugates consisting of a specific binding partner and a carbohydrate-containing protein
AU1179695A (en) (vibrio cholerae) bengal serogroup-0139 capsular polysaccharide, protein conjugates thereof and antibodies induced thereby
DE59611293D1 (de) Protein mit dnase-aktivität
ES2170161T3 (es) Nuevos conjugados de principios activos y proteinas.
ATE252593T1 (de) Glykosidierung von 4,5-epoxymorphinan-6-olen